The peroxisome proliferator-activated receptor-γ agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance

Diabetes

Volumn 56, Issue 10, 2007, Pages 2609-2615

  Werner, Christian ^a   Kamani, Christel Hermann ^a   Gensch, Christoph ^a   Böhm, Michael ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' DIOCTADECYL 3,3,3',3' TETRAMETHYLINDOCARBOCYANINE; 2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; C REACTIVE PROTEIN; CD34 ANTIGEN; GLUCOSE; LECTIN; LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; ATHEROSCLEROSIS; CELL COUNT; CELL CULTURE; CELL FUNCTION; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CLONOGENESIS; COLONY FORMING UNIT; COMPLIANCE (PHYSICAL); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOCUMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; IMPAIRED GLUCOSE TOLERANCE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STEM CELL; UPREGULATION;

ADIPONECTIN; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CORONARY DISEASE; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; PPAR GAMMA; PROSPECTIVE STUDIES; REFERENCE VALUES; STEM CELLS; THIAZOLIDINEDIONES;

EID: 34948859481     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db07-0069     Document Type: Article

References (49)

1. Schoonjans K, Auwerx J: Thiazolidinediones: an update. Lancet 355:1008-1010, 2000
2. Hetzel J, Balletshofer B, Rittig K, et al.: Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 25:1804-1809, 2005
3. Pfutzner A, Marx N, Lubben G, et al.: Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45:1925-1931, 2005
4. Pistrosch F, Passauer J, Fischer S, et al.: In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27:484-490, 2004
5. Chen Z, Ishibashi S, Perrey S, et al.: Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21:372-377, 2001
6. Li AC, Brown KK, Silvestre MJ, et al.: Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531, 2000
7. Mazzone T, Meyer PM, Feinstein SB, et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572-2581, 2006
8. Marx N: Peroxisome proliferator-activated receptor gamma and atherosclerosis. Curr Hypertens Rep 4:71-77, 2002
9. Marx N, Duez H, Fruchart JC, et al.: Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94:1168-1178, 2004
10. Plutzky J: Medicine. PPARs as therapeutic targets: reverse cardiology? Science 302:406-407, 2003
11. Asahara T, Murohara T, Sullivan A, et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
12. Rafii S, Lyden D: Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9:702-712, 2003
13. Dimmeler S, Aicher A, Vasa M, et al.: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108:391-397, 2001
14. Hill JM, Zalos G, Halcox JP, et al.: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593-600, 2003
15. Walter DH, Rittig K, Bahlmann FH, et al.: Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105:3017-3024, 2002
16. Aicher A, Heeschen C, Mildner-Rihm C, et al.: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9:1370-1376, 2003
17. Strehlow K, Werner N, Berweiler J, et al.: Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107:3059-3065, 2003
18. Werner N, Junk S, Laufs U, et al.: Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 93:e17-e24, 2003
19. Schachinger V, Assmus B, Honold J, et al.: Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy: intracoronary Doppler substudy of the TOPCARE-AMI trial. Clin Res Cardiol 95:13-22, 2006
20. Werner N, Kosiol S, Schiegl T, et al.: Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999-1007, 2005
21. Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al.: Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111:2981-2987, 2005
22. Tepper OM, Galiano RD, Capla JM, et al.: Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106:2781-2786, 2002
23. Shintani S, Murohara T, Ikeda H, et al.: Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103:2776-2779, 2001
24. Werner N, Priller J, Laufs U, et al.: Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 22:1567-1572, 2002
25. Vasa M, Fichtlscherer S, Aicher A, et al.: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89:E1-E7, 2001
26. Fadini GP, Sartore S, Albiero M, et al.: Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 26:2140-2146, 2006
27. Ii M, Takenaka H, Asai J, et al.: Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. Circ Res 98:697-704, 2006
28. Adams V, Lenk K, Linke A, et al.: Increase of circulating endothelial progenitor cells in patients with coronary artery disease after exercise-induced ischemia. Arterioscler Thromb Vasc Biol 24:684-690, 2004
29. Laufs U, Werner N, Link A, et al.: Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109:220-226, 2004
30. Kusuyama T, Omura T, Nishiya D, et al.: Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J Pharmacol Sci 102:96-102, 2006
31. Wang CH, Ting MK, Verma S, et al.: Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J 152:1051-1058, 2006
32. Wang CH, Ciliberti N, Li SH, et al.: Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109:1392-1400, 2004
33. Pistrosch F, Herbrig K, Oelschlaegel U, et al.: PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis 183:163-167, 2005
34. Gensch C, Clever YP, Werner C, et al.: The PPA: R-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis 192:67-74, 2007
35. Laufs U, Urhausen A, Werner N, et al.: Running exercise of different duration and intensity: effect on endothelial progenitor cells in healthy subjects. Eur J Cardiovasc Prev Rehabil 12:407-414, 2005
36. Maack C, Kartes T, Kilter H, et al.: Oxygen free radical release in human failing myocardium is associated with increased activity of Rac1-GTPase and represents a target for statin treatment. Circulation 108:1567-1574, 2003
37. Semple RK, Chatterjee VK, O'Rahilly S: PPAR gamma and human metabolic disease. J Clin Invest 116:581-589, 2006
38. Ray R, Shah AM: NADPH oxidase and endothelial cell function. Clin Sci (Lond) 109:217-226, 2005
39. Imanishi T, Hano T, Nishio I: Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens 23:97-104, 2005
40. Thum T, Fraccarollo D, Thum S, et al.: Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol 27:748-754, 2007
41. Marx N: PPARgamma and vascular inflammation: adding another piece to the puzzle. Circ Res 91:373-374, 2002
42. Fujii H, Li SH, Szmitko PE, et al.: C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 26:2476-2482, 2006
43. Verma S, Kuliszewski MA, Li SH, et al.: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109:2058-2067, 2004
44. Urbich C, Dimmeler S: Endothelial progenitor cells functional characterization. Trends Cardiovasc Med 14:318-322, 2004
45. Turnbull F, Neal B, Algert C, et al.: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165:1410-1419, 2005
46. Costa J, Borges M, David C, et al.: Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332:1115-1124, 2006
47. Richter B, Bandeira-Echtler E, Bergerhoff K, et al.: Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev CD006060, 2006
48. Marx N, Wohrle J, Nusser T, et al.: Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112:2792-2798, 2005
49. Horio T, Suzuki M, Takamisawa I, et al.: Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am J Hypertens 18:1626-1630, 2005